ARCH Venture Partners, a venture capital firm, led a $270m Series A funding round in Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, with participation from a16z Bio + Health and Newpath Partners, and new investors Abu Dhabi Growth Fund, Redmile Group, Exor, Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems. “Few companies can possess the know-how, technology and biologic insights to deliver on the full breadth of opportunity that RNA medicines could provide for patients. Orbital was founded and has been built to be that special company. We are pleased to partner with Orbital’s team of industry leaders and visionaries in drug development to help them achieve a bold mission of bringing forward the next generation of RNA-based medicines,” Kristina Burow, ARCH Venture Partners Managing Partner.